AMR

Meguro-ku, Japan
Meguro-ku, Japan
SEARCH FILTERS
Time filter
Source Type

News Article | April 18, 2017
Site: www.prweb.com

For a historic seventh consecutive year, Benchmark Research along with PMG Research Associates and Miami Research Associates, co-members in the VaxCorps vaccine consortium, were named one of the top two Clinical Research Sites or Network. Benchmark Research has been a top finalist since the inception of this category; winning the award four times previously, and first runner up the other three years. The only awards ceremony dedicated to the vaccine industry, the annual Vaccine Industry Excellence (ViE) Awards honor individuals, organizations and initiatives which have made significant contributions to the industry over the past 12 months. “We congratulate Brenda Atchison and AMR for their well-deserved win this year, and thank our partners in VaxCorps, PMG and QPS/MRA for working with Benchmark to become the unparalleled vaccine network in the world. We are also deeply grateful to have been in the top two sites/networks for seven consecutive years, and are proud that no other company has achieved these accolades in any other category. Finally, and most importantly, we are blessed by all the Benchmark Family employees who ultimately are responsible for this prestigious award," said Mark Lacy, CEO of Benchmark Research. Benchmark Research is a fully integrated network of multi-therapeutic research sites, spanning three states. With the innovative opening of three Urgent & Family Care Centers this past year, Benchmark Research is enhancing the company patient database, taking on a broader spectrum of indications and is bringing added value to patients and clients. Started in 1997, Benchmark Research continues to lead in the quest to provide excellence in the clinical research industry.


News Article | May 4, 2017
Site: www.fao.org

img src="http://www.fao.org/figis/servlet/IRS?iid=54924 " alt="Click to enlarge"/ Click for enlarged image The development of resistant strains of disease-causing microorganisms is an important health issue of global concern. When microbes such as bacteria, fungi, parasites, and viruses become resistant to antimicrobial substances, the diseases they may cause become more difficult or impossible to treat. Resistance is developed by the indiscriminate use of antimicrobials and places human health at risk. The discovery of antibiotics revolutionized medicine, creating a belief that a 'magic bullet' had finally been found to control bacterial diseases. Antibiotics, a class of antimicrobial agents, kill or inhibit the growth of bacteria, but they have no significant effect on other types of microorganisms such as viruses. "Bacteria, the oldest life form on this planet have survived 4 billion years due to their remarkable ability to adapt to changes in their environment... any 'resistance' gene present in any member of any species in the microbiome has the potential to transfer to any other species" says Dr Peter Smith of Ireland. National delegates representing China, Malaysia, the Philippines and Viet Nam; fish health experts from India, Ireland, the Netherlands, the Philippines, Viet Nam and the United States; and representatives of the Government of India, Nitte University, FAO, NACA and the OIE are participating at an international workshop to address antimicrobial use (AMU) and AMR in aquaculture, convened by FAO and Nitte University, in Mangalore, India, 10-12 April. Dr J.K. Jena, Deputy Director General of the Indian Council of Agricultural Research, highlighted the importance of aquaculture and the need to address issues related to diseases and the irresponsible use of veterinary drugs. "Strengthening laboratory networks and increasing AMU/AMR awareness as well as research on safety, efficacy and withdrawal period, resistance mode and process of transfer of resistance for different antimicrobials are needed", he said. In his Presidential Address, the Vice-Chancellor of Nitte University, Professor Ramananda Shetty, urged interdisciplinary studies to be undertaken as all sectors have a responsibility towards this burning problem. He emphasized the need for regulation of antibiotic sales, responsible implementation of treatment regimens by the doctors and diligent attention to medical advice by the patients. The complexity of the issue calls for a "One Health" platform involving both human medicine and the agriculture sector in an interdisciplinary and integrated approach to tackle what is very much a common problem. This approach combined with concerted actions at the national level that span policy and regulatory spheres, preventive actions and engagement with producers and other food value chain stakeholders are needed to prevent and reduce AMR. Detailed guidance was provided on developing the aquaculture component of the National Action Plans (NAP) on AMR covering the four focus areas of FAO's Action Plan on AMR: awareness, governance (NAP), evidence (usage and surveillance) and practice (prudent use). National delegates will further develop the action plans, disseminate the scientific information delivered during the workshop and create awareness of AMR issues among national stakeholders.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "VoLTE Services & Subscribers Market Report - Regional 2016" report to their offering. The VoLTE Services & Subscribers Market Report provides accurate data and analyses - including market size, forecasts, and market trends - to help clients make better business decisions in the mobile VoIP services and subscribers market. - VoLTE Deployment Tracker lists deployments by service provider and start date for VoLTE and deployments by provider - Analyst-led conference call with presentation, plus one-on-one time with the analyst to ask questions I. Top Takeaways: VoLTE Is Ramping Up, but Revenue Remains to Be Seen II. VoLTE Is Quickly Ramping Up, with Improvements in Network Efficiencies as the Chief Driver a. In each of those 63 VoLTE networks, existing subscribers become de facto VoLTE users when they upgrade their device to an LTE-capable one b. The ramp up is good news but there is still no rush, even with the ecosystem in place, barriers removed and issues solved. . . c. . . . but in the meantime, the VoLTE front runners are ramping up VoLTE users! Asia Pacific is poised for driving the VoLTE market through 2020 For VoLTE related revenue, we looked at existing voice plans d. VoLTE roaming is the next big thing, fueling the LBO (RAVEL) vs. S8HR debate e. Meanwhile, the pace of commercialization of 3G mobile W-AMR HD voice continues to grow. . . f. . . . And native mVoIP has been available for some time g. Technical issues inherent to 3G are fixed but there is still no incentive to offer mVoIP as a service; good old voice is still good For more information about this report visit http://www.researchandmarkets.com/research/l8fw4m/volte_services


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Smart Gas Market - Global Forecast to 2022" report to their offering. The smart gas market size is expected to grow from USD 11.25 billion in 2017 to USD 21.75 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 14.1% during the period of 2017-2022. The major drivers for upsurge in demand for the smart gas market include the growing demand for customer-centric approach and increasing global energy demand leading to adoption of sophisticated technologies and integrated wireless communication features in smart gas solutions reducing field visits. The limiting factors hindering the growth of the smart gas market include the lack of strong business case for the deployment of smart gas meters limiting the investment and the high Capital Expenditure (CAPEX) on the smart gas infrastructure. Meter data analytics solution unlocks smart meter data from both Automatic Meter Reading (AMR) and Advanced Metering Infrastructure (AMI) sources, turning them into actionable information for gas utilities. It enables the company staff to track performance and analyze trends using the information from the core gas utility applications. It helps improve customer service quality and cut costs by using Interactive Voice Response (IVR) systems, steering customers to self-service websites and varying billing cycles, so that call volumes are relatively leveled l throughout the month. It also reduces gas loss, resulting from pipe leaks and breaks by analyzing sensor data in near real-time to detect unusual flow rates and automatically notify dispatchers & field technicians about likely emergencies. For more information about this report visit http://www.researchandmarkets.com/research/9wdtmb/smart_gas_market


News Article | April 28, 2017
Site: www.prnewswire.com

The public 'Call to Action' launched in Berlin on April 28 urges G20 health ministers to commit new long-term investment in pandemic preparedness, and health technologies to combat antimicrobial resistance(AMR) and Poverty-Related and Neglected Diseases(PRNDs). "Meeting health targets outlined in the UN Sustainable Development Goals will require sustained investment and political will," coalition representatives said. "As representatives of the world's largest and wealthiest economies, the G20 must provide leadership. As we saw during the recent Ebola crisis in West Africa, the world is woefully unprepared to deal with pandemics. AMR, which includes drug resistant strains of HIV/AIDS, TB, malaria, diarrheal disease and pneumonia also poses an increasingly serious threat to public health." We urge the G20 to agree to provide the following: "These are diseases of poverty: 95% of cases are among poor and marginalised populations in low and middle-income countries. They also fuel the cycle of poverty, exacting a heavy economic toll on affected families and communities, which imposes a significant 'growth penalty' on entire regions. "Failure to invest now will lead to long-term costs. The World Bank has estimated that, without additional resources, these diseases will push an additional 28.3million people into poverty, increase global healthcare costs by $1.2trillion and cost low income countries more than 5% of GDP by 2050. "G20 leadership is vital if we are to successfully reduce the global disease burden, lift millions out of poverty and avert billions of dollars of economic and social costs." 1-The 'Call to Action' is launched today at G20 Global Health Innovation event in Berlin. 2-G20 health ministers meeting take places on May 19/20. For more information/interviews with Coalition:


News Article | April 28, 2017
Site: www.prnewswire.co.uk

The public 'Call to Action' launched in Berlin on April 28 urges G20 health ministers to commit new long-term investment in pandemic preparedness, and health technologies to combat antimicrobial resistance(AMR) and Poverty-Related and Neglected Diseases(PRNDs). "Meeting health targets outlined in the UN Sustainable Development Goals will require sustained investment and political will," coalition representatives said. "As representatives of the world's largest and wealthiest economies, the G20 must provide leadership. As we saw during the recent Ebola crisis in West Africa, the world is woefully unprepared to deal with pandemics. AMR, which includes drug resistant strains of HIV/AIDS, TB, malaria, diarrheal disease and pneumonia also poses an increasingly serious threat to public health." We urge the G20 to agree to provide the following: "These are diseases of poverty: 95% of cases are among poor and marginalised populations in low and middle-income countries. They also fuel the cycle of poverty, exacting a heavy economic toll on affected families and communities, which imposes a significant 'growth penalty' on entire regions. "Failure to invest now will lead to long-term costs. The World Bank has estimated that, without additional resources, these diseases will push an additional 28.3million people into poverty, increase global healthcare costs by $1.2trillion and cost low income countries more than 5% of GDP by 2050. "G20 leadership is vital if we are to successfully reduce the global disease burden, lift millions out of poverty and avert billions of dollars of economic and social costs." 1-The 'Call to Action' is launched today at G20 Global Health Innovation event in Berlin. 2-G20 health ministers meeting take places on May 19/20. For more information/interviews with Coalition:


News Article | April 24, 2017
Site: www.marketwired.com

TORONTO, ONTARIO--(Marketwired - April 24, 2017) - Asian Mineral Resources Limited ("AMR" or the "Company") (TSX VENTURE:ASN) is pleased to announce that it has entered into a net smelter royalty return agreement (the "NSR Agreement") with Cobalt 27 Capital Corp. ("Cobalt 27") related to the sale of cobalt by AMR from its Ta Khoa concession in Vietnam. Under the terms of the NSR Agreement, AMR will receive C$300,000 equivalent in common shares of Cobalt 27 in exchange for granting Cobalt 27 a 3% net smelter return on sales of cobalt from the Ta Khoa concession. The price per common share will be equal to the price per common share offered by Cobalt 27 pursuant to its offering of common shares (the "Cobalt 27 Offering") under its preliminary prospectus dated April 21, 2017. Receipt of the common shares from Cobalt 27 as payment and the effectiveness of the NSR Agreement is dependent on certain matters being completed, including the receipt of material third party consents and the closing of the Cobalt 27 Offering, on or before September 30, 2017. AMR owns and operates one of the world's few sources of nickel sulphide ore, and is exploring for additional high-grade nickel assets in Vietnam. AMR commenced commercial production from its 90%- owned Ban Phuc Nickel Mine in Vietnam in mid-2013. As of 30 June 2016, the Ban Phuc Nickel Mine has produced a total of c. 20,000 tonnes of nickel and c. 10,000 tonnes of copper contained in concentrate, plus a cobalt by-product since the beginning of its mine life. Mining and processing operations at Ban Phuc were suspended in September 2016 and operations were transitioned to a care and maintenance scenario. In addition to in and near-mine expansion projects, Ban Phuc provides a platform from which AMR can continue to focus on developing a new nickel camp within its 150km2 of concessions located throughout the highly-prolific Song Da rift zone, where AMR has a number of advanced-stage nickel exploration targets. For further details on AMR, please refer to the technical report entitled "NI 43-101 Technical Report - Ban Phuc Nickel Project" dated February 15, 2013 available on SEDAR or the AMR website www.asianmineralres.com. This press release includes certain "Forward-Looking Statements." All statements, other than statements of historical fact, included herein, including without limitation, the completion of conditions precedent under the NSR Agreement, completion of the Cobalt 27 financing and receipt of payment under the NSR Agreement, potential mineralization and reserve and resource estimates, exploration results and future plans and objectives of AMR are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of AMR to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results to differ materially from AMR's expectations are disclosed under the heading "Risk Factors" in AMR's Annual Information Form, and elsewhere in AMR's documents filed from time-to-time with the TSX Venture Exchange and other regulatory authorities. Such forward-looking statements are based on a number of material factors and assumptions, including: that contracted parties provide goods and/or services on the agreed timeframes; that parties are able to complete financings on agreeable terms; that third parties provide required consents acting reasonably; that on-going contractual negotiations will be successful and progress and/or be completed in a timely manner; that application for permits and licences will be granted/obtained in a timely manner; that no unusual geological or technical problems occur; that plant and equipment work as anticipated and that there is no material adverse change in the price of applicable minerals and metals. Although AMR has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are made as of the date of this press release. AMR disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements due to the inherent uncertainty therein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


News Article | April 20, 2017
Site: www.theguardian.com

The stark impact of antimicrobial resistance is all around us. Just a few weeks ago, a woman in the US who could not be treated with any available antibiotics (26 to be precise) died. And recently, results of a study demonstrated that four patients had malaria that was resistant to the most commonly used antimalarial in the UK. Similarly, we are seeing outbreaks of both gonorrhoea and fungal infections that are multi-resistant. The failure of treatment for gonorrhoea has been confirmed in at least 10 countries including the UK, Australia, Canada and France. Antimicrobial resistance is more common in some parts of the world than others. For example, it was estimated that there were 214,000 neonatal deaths attributable to resistant sepsis infections globally in 2013. 111,523 of these occurred in the five countries with the highest numbers of neonatal deaths in the world: India, Pakistan, Nigeria, Democratic Republic of Congo and China. A major area of concern for health professionals is drug-resistant tuberculosis. The World Health Organisation estimates that in 2014, there were about 480,000 new cases of multi-drug resistant tuberculosis (MDR-TB), a form of tuberculosis that is resistant to the two most powerful anti-TB drugs. Soaring rates of multi-drug resistant tuberculosis have been found in west Africa, with the highest in the dense population of Lagos, Nigeria, suggesting the seriousness of the epidemic has been considerably underestimated. Although there is a lot of talk about antibiotic resistance in the future, it is important to realise that we are already seeing the impact of resistant infections in everyday life. Many urinary tract infections are becoming resistant, which can lead to people requiring a hospital stay. Sally Davies, chief medical officer for England, warned last year that 50,000 people are dying every year in Europe and the US from infections that antibiotics have lost the power to treat. Resistance is not a new problem. Alexander Fleming (1881–1955), who discovered penicillin, warned of the risk of resistance developing as far back as 1945. During his Nobel prize speech in 1945 he said: “The microbes are educated to resist penicillin and a host of penicillin-fast organisms is bred out which can be passed on to other individuals and perhaps from there to someone else and to others until they reach someone with a pneumonia which penicillin cannot save. I hope this evil can be averted.” Having fewer antibiotics that work will be equivalent to going back to the early 1930s, where infections we now consider trivial thanks to quick treatment by antibiotics will once again be fatal. An infected cut or illness such as pneumonia could once again become mass killers. Resistance is an expected consequence of antibiotic use and its spread is a result of poor infection prevention and control. A recent global review on antimicrobial resistance (AMR) highlighted that if we do not act now to tackle AMR, infections that are resistant to antimicrobials will kill 10 million people by 2050, and that between 2016 and 2050 the world could expect to lose between $60tn and $100tn worth of economic output [pdf]. The impact of such a cost has been likened by the World Bank to that caused by the 2008 financial crisis. Our Antibiotic Guardian campaign allows everyone to sign up to a pledge, health professionals or members of the public. Midwives can pledge to make sure mothers are only given drugs they need and know how to use them. Dentists can pledge to consider drainage for dental issues before using antibiotics. Farmers can pledge to annually review and discuss the antibiotic use on their farm with a vet, and look for ways of optimising use as necessary. We want people to learn what actions they can personally take to help tackle the problem. Evaluation of the initiative shows that the campaign changes behaviour and increases knowledge and also increases commitment to tackling AMR. We are also aiming to educate children about the importance of antibiotics. The E-Bug school programme provides resources and educational games in 22 languages covering infection protection and control as well as explaining antibiotics. In addition to ensuring we make appropriate use of antibiotics for human health, AMR has clear links to both animal health, farming and the environment. The importance of tackling AMR using what we call a “one health” approach is now widely recognised. The approach is defined as “... the collaborative effort of multiple disciplines to attain optimal health for people, animals and our environment …”. In the UK, for example, the strategy to tackle antimicrobial resistance takes a one health approach with actions for human, animal and environmental health. No new class of antibiotics has been discovered for a number of years. Even if we discover more, simply replacing old antibiotics with new ones is not the only answer as they could also become ineffective. It is therefore important that everyone does their part to tackle this issue. Diane Ashiru-Oredope is pharmacist lead for antimicrobial resistance and stewardship at Public Health England. Join our community of development professionals and humanitarians. Follow @GuardianGDP on Twitter.


NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced the launch of the company’s Antimicrobial Testing Leadership and Surveillance (ATLAS) website, which is designed to provide physicians and the global health community with easy access to critical data on the efficacy of various antibiotic treatments and emerging resistance patterns across more than 60 countries. Understanding evolving bacterial resistance patterns is a key element in managing the rise of antimicrobial resistance. To that end, ATLAS can not only help physicians select the most appropriate treatment choices for their patients, but also enable global health authorities to develop data-driven antimicrobial resistance mitigation strategies. Pfizer will formally unveil ATLAS on April 22nd at the annual meeting of the European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna. Mobile devices and applications provide many benefits for healthcare professionals including increased access to point of care tools, which have been shown to support better clinical decision making and improved patient outcomes. In response to this need, Pfizer also offers ATLAS as a mobile application to enable rapid access to important resistance information at the point of patient care. ATLAS offers an interactive platform that enables physicians to evaluate data, conduct analyses, and export tables and figures that include parameters such as pathogen, region, specimen source and in vitro susceptibility data. The ATLAS database is updated every six months with new resistance data from healthcare institutions in more than 60 countries as these become available. ATLAS can be accessed by visiting: www.atlas-surveillance.com. “An important aspect for physicians when treating patients is knowledge; knowledge of where certain resistant bacterial infections tend to occur and knowledge of which antibiotics remain effective against them,” said Dr. Freda Lewis-Hall, Chief Medical Officer of Pfizer Inc. “ATLAS underscores our continued commitment to providing patients and physicians with meaningful resources that can help ensure appropriate utilization of antibiotics and improve infection prevention and control.” The World Health Organization (WHO) characterizes antimicrobial resistance as one of the biggest threats to global health, that can affect anyone at any age in any country, threatening our ability to treat serious infections and provide standard medical procedures. Gram-negative bacteria, the cause of many healthcare-associated infections (HAIs), have become increasingly resistant to many available antibiotic treatments. These infections are associated with increased patient mortality and cost of care. At present, approximately 700,000 deaths per year are attributed to antimicrobial resistance globally, with an increase to 10 million predicted by 2050 if no action is taken to address this issue. Today, Pfizer is the leading global provider of anti-infective medicines in the industry, offering patients access to a diverse portfolio of more than 80 products. Pfizer recognizes the serious public health threat associated with AMR and has taken significant steps to address this issue. In early 2016, Pfizer was a signatory of the Declaration on Combating Antimicrobial Resistance (AMR), a global call-to-action drafted and signed by more than 100 companies and 13 trade associations encouraging greater industry and government collaboration to address the issue of antimicrobial resistance. As a follow-up to the AMR Declaration, Pfizer and 13 industry partners unveiled the “Industry Roadmap to Combat Antimicrobial Resistance,” a comprehensive plan of action, that lays out four key commitments we pledge to deliver by 2020. For more information on Pfizer’s commitment to AMR, please click here. Since its pioneering work on penicillin in the 1940s, Pfizer has been actively engaged in the research and development of innovative medicines, policies and educational programs to address the evolving needs of patients and physicians in the area of infectious diseases. For more than 30 years, Pfizer has been a leader in developing and implementing innovative public-private partnerships designed to address unmet medical needs and global public health issues. Today, our patient assistance programs expand access to potentially lifesaving medicines and provide educational resources that empower patients and physicians in the fight against infectious disease. Pfizer Inc.: Working together for a healthier world® At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @PfizerNews, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.


Smart Gas Market size will grow from $11.25billion in 2017 to $21.75billion by 2022, at a CAGR of 14.1%. Major drivers of Smart Gas Industry are growing demand for customer-centric approach, increasing energy demand, integrated wireless communication features in smart gas solutions reducing field visits.Pune, India - April 24, 2017 /MarketersMedia/ — Increasing global energy demand, replacement of aging infrastructure, and growing demand for customer-centric approach is expected to drive the growth of the smart gas market The Smart Gas Market size is expected to grow from USD 11.25 billion in 2017 to USD 21.75 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 14.1% during the period of 2017–2022. The major drivers for upsurge in demand for the smart gas market include the growing demand for customer-centric approach and increasing global energy demand leading to adoption of sophisticated technologies and integrated wireless communication features in smart gas solutions reducing field visits. The limiting factors hindering the growth of the smart gas market include the lack of strong business case for the deployment of smart gas meters limiting the investment and the high Capital Expenditure (CAPEX) on the smart gas infrastructure. Download Sample Copy of Report At: https://goo.gl/9KHSQT Analytics and data management solution is estimated to have the largest market share during the forecast period Meter data analytics solution unlocks smart meter data from both Automatic Meter Reading (AMR) and Advanced Metering Infrastructure (AMI) sources, turning them into actionable information for gas utilities. It enables the company staff to track performance and analyse trends using the information from the core gas utility applications. It helps improve customer service quality and cut costs by using Interactive Voice Response (IVR) systems, steering customers to self-service websites and varying billing cycles, so that call volumes are relatively levelled throughout the month. It also reduces gas loss, resulting from pipe leaks and breaks by analysing sensor data in near real-time to detect unusual flow rates and automatically notify dispatchers &field technicians about likely emergencies. Asia-Pacific (APAC) is expected to grow at the fastest rate in the market during the forecast period As per the geographic analysis, the APAC region would witness the fastest growth in the smart gas market over the forecast period, due to the increasing adoption of smart grid architecture, technology upgrades, energy management, regulatory mandates, and affluent countries, such as China, Australia, South Korea, Japan, Singapore, &Hong Kong, which are the major contributing factors for the growth of smart gas solutions in this region. The increasing smart meter rollouts for residential customers in countries, such as China, Japan, Australia, and South Korea have bolstered the growth of smart gas metering in the region. In countries, such as Philippines, Indonesia, Thailand, and India, the political push &privatization are the major drivers for the growth of Internet of Things (IoT) adoption. Ambitious rollout plans in India have stagnated due to a number of factors, including legislative obstacles &bottlenecks, economic downturns, lack of customer engagement, and network infrastructure-related issues. In the process of determining and verifying the market size for several segments & sub segments gathered through secondary research, extensive primary interviews were conducted with key industry personnel. The break-up profiles of primary discussion participants are given below: • By Company Type: Tier-1 (44%), Tier-2 (37%), and Tier-3 (19%) • By Designation: C-Level (65%) and Manager Level (35%) • By Region: North America (33%), Europe (44%), APAC (18%), and the Rest of World (RoW) (5%) Inquire For More Info About Smart Gas Market Research Report At: https://goo.gl/9KAbcW The various key smart gas market vendors profiled in the report are as follows: • ABB Group (Zurich, Switzerland) • Aclara Technologies LLC (Hazelwood, Missouri) • Badger Meter, Inc. (Wisconsin, U.S.) • Cap Gemini S.A. (Paris, France) • CGI Group Inc. (Montreal, Canada) • Diehl Stiftung & Co KG (Nuremberg, Germany) • Elster Group GmbH (New Jersey, U.S.) • General Electric Company (Massachusetts, U.S.) • IBM Corporation (New York, U.S.) • Itron Inc. (Washington, U.S.) • Landis+Gyr (Zug, Switzerland) • Oracle Corporation (California, U.S.) • Schneider Electric SE (Rueil-Malmaison, France) • Sensus USA Inc. (North Carolina, U.S.) • Silver Spring Networks, Inc. (California, U.S.) • Verizon Communications, Inc. (New York, U.S.) Research Coverage : The global smart gas market has been segmented on the basis of types (solution, service, &device) and regions. A detailed analysis of the regions has been done to provide insights into the potential future business opportunities across different regions. In addition to this, the product portfolio analysis and business strategy analysis are the other MarketsandMarkets analysis included in the report. Reasons to Buy the Report : The report will help the market leaders/new entrants in this market in the following ways: • This report segments the smart gas market comprehensively and provides the closest approximations of the revenue numbers for the overall market & sub segments across different regions. • The report helps the stakeholders understand the pulse of the market and provides them information on key market drivers, restraints, challenges, & opportunities. • This report helps the stakeholders to better understand the competitors and gain more insights to better their positions in the business. About Us: ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more. Connect with Us: LinkedIn: www.linkedin.com/company/reportsnreports RSS/Feeds: http: //www.reportsnreports.com/feed/l-latestreports.xml Contact Info:Name: Ritesh TiwariEmail: sales@reportsandreports.comOrganization: ReportsnReportsAddress: 2nd floor, metropole, Next to inox theatre, Bund garden road, Pune-411001Phone: + 1 888 391 5441Source URL: http://marketersmedia.com/smart-gas-market-growth-at-14-1-cagr-to-2022asia-pacific-expected-to-grow-at-fastest-rate-in-global-market/189533For more information, please visit http://www.rnrmarketresearch.com/smart-gas-market-by-devices-smart-gas-meters-amr-gas-meters-communication-modules-solutions-scada-gis-eam-mobile-workforce-management-mdm-analytics-leak-detection-services-worldwide-ma-market-report.htmlSource: MarketersMediaRelease ID: 189533

Loading AMR collaborators
Loading AMR collaborators